Rhumbline Advisers Buys 4,366 Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC)

Rhumbline Advisers grew its stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) by 4.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 100,015 shares of the company’s stock after acquiring an additional 4,366 shares during the quarter. Rhumbline Advisers’ holdings in C4 Therapeutics were worth $360,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Point72 DIFC Ltd acquired a new stake in shares of C4 Therapeutics during the 3rd quarter worth approximately $51,000. Cynosure Group LLC bought a new stake in C4 Therapeutics during the third quarter worth $57,000. Aigen Investment Management LP acquired a new stake in shares of C4 Therapeutics in the 3rd quarter valued at $82,000. China Universal Asset Management Co. Ltd. bought a new position in shares of C4 Therapeutics in the 4th quarter valued at $54,000. Finally, Intech Investment Management LLC bought a new position in shares of C4 Therapeutics in the 3rd quarter valued at $155,000. 78.81% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on CCCC shares. Stephens started coverage on shares of C4 Therapeutics in a report on Monday, November 18th. They issued an “equal weight” rating and a $4.00 target price for the company. UBS Group raised shares of C4 Therapeutics to a “hold” rating in a research note on Friday, February 14th. Finally, Wells Fargo & Company raised shares of C4 Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $8.00 to $12.00 in a research note on Thursday, December 19th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, C4 Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.

C4 Therapeutics Price Performance

CCCC stock opened at $2.36 on Monday. C4 Therapeutics, Inc. has a 1 year low of $2.21 and a 1 year high of $11.48. The stock has a market capitalization of $167.54 million, a PE ratio of -1.39 and a beta of 2.99. The company’s 50-day moving average is $3.36 and its 200-day moving average is $4.66.

C4 Therapeutics (NASDAQ:CCCC) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.05). The business had revenue of $5.18 million for the quarter, compared to analyst estimates of $4.43 million. C4 Therapeutics had a negative return on equity of 42.45% and a negative net margin of 313.35%. On average, analysts anticipate that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current fiscal year.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.